Hosted on MSN3m
BofA reiterates Buy on Novo Nordisk shares on performanceBofA believes that the issues will likely resolve in Novo Nordisk's favor. The firm also discussed the double-edged nature of Novo Nordisk's Semaglutide high dose obesity Phase III study. On one hand, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback